PMID- 23396736
OWN - NLM
STAT- MEDLINE
DCOM- 20131017
LR  - 20190919
IS  - 1665-2681 (Print)
IS  - 1665-2681 (Linking)
VI  - 12
IP  - 2
DP  - 2013 Mar-Apr
TI  - Addition of pentoxifylline to pegylated interferon-alpha-2a and ribavirin 
      improves sustained virological response to chronic hepatitis C virus: a 
      randomized clinical trial.
PG  - 248-55
AB  - BACKGROUND AND AIM: The commonly accepted treatment for hepatitis C virus (HCV) 
      infection, pegylated interferon alpha (PEG INF-alpha) and ribavirin, leads to 
      50-60% of sustained virological response (SVR). On the other hand, pentoxifylline 
      (PTX) possesses antiviral and hepatoprotector properties. AIM: To investigate 
      whether the addition of PTX to conventional hepatitis C treatment increases SVR. 
      MATERIAL AND METHODS: Seventy two patients of both genders were studied in a 
      randomized fashion; the diagnosis of chronic HCV infection was made according to 
      clinical and laboratory criteria and histopathologically classified according to 
      METAVIR scoring system criteria. HCV viral load was tested by PCR, baseline, and 
      after 6 months of treatment, as well as anti-HCV, anti-hepatitis B virus , and 
      anti-human immunodeficiency virus antibodies by enzyme-linked immunosorbent 
      assay. During 48 weeks, control group patients were treated with PEG INF-alpha- 
      2a plus ribavirin. PTX was administered to Experimental Group patients prior to 
      the treatment. RESULTS: Demographic data were similar in both groups. 
      Experimental- and control-group subjects were at F2 and F3 states according to 
      the METAVIR classification. The most common HCV genotypes were 1a and 1b (39% in 
      the control group in each case, and 42% in the experimental group in each case). 
      At the end of the study, hepatic enzymes and viral load decreased in both groups 
      to similar values. SVR in the experimental group increased significantly (p < 
      0.05) when compared with standard therapy alone. CONCLUSION: Addition of PTX to 
      conventional chronic hepatitis C treatment may increase the percentage of 
      patients with SVR.
FAU - Jimenez-Luevano, Miguel Angel
AU  - Jimenez-Luevano MA
AD  - Servicio de Gastroenterologia, Hospital Valentin Gomez Farias, Instituto de 
      Seguridad y Seguro Social de los Trabajadores del Estado (ISSSTE), Zapopan, 
      Jalisco, Mexico.
FAU - Lerma-Diaz, Jose Manuel
AU  - Lerma-Diaz JM
FAU - Hernandez-Flores, Georgina
AU  - Hernandez-Flores G
FAU - Jimenez-Partida, Miguel Angel
AU  - Jimenez-Partida MA
FAU - Bravo-Cuellar, Alejandro
AU  - Bravo-Cuellar A
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Mexico
TA  - Ann Hepatol
JT  - Annals of hepatology
JID - 101155885
RN  - 0 (Antiviral Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Hepatitis C Antibodies)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - Q46947FE7K (peginterferon alfa-2a)
RN  - SD6QCT3TSU (Pentoxifylline)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antiviral Agents/adverse effects/*therapeutic use
MH  - Biomarkers/blood
MH  - Chi-Square Distribution
MH  - Drug Therapy, Combination
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Hepacivirus/genetics/immunology
MH  - Hepatitis C Antibodies/blood
MH  - Hepatitis C, Chronic/blood/diagnosis/*drug therapy
MH  - Humans
MH  - Interferon-alpha/adverse effects/*therapeutic use
MH  - Male
MH  - Mexico
MH  - Middle Aged
MH  - Pentoxifylline/adverse effects/*therapeutic use
MH  - Pilot Projects
MH  - Polyethylene Glycols/adverse effects/*therapeutic use
MH  - Polymerase Chain Reaction
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Recombinant Proteins/adverse effects/therapeutic use
MH  - Ribavirin/adverse effects/*therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
MH  - Viral Load
EDAT- 2013/02/12 06:00
MHDA- 2013/10/18 06:00
CRDT- 2013/02/12 06:00
PHST- 2013/02/12 06:00 [entrez]
PHST- 2013/02/12 06:00 [pubmed]
PHST- 2013/10/18 06:00 [medline]
AID - S1665-2681(19)31363-8 [pii]
PST - ppublish
SO  - Ann Hepatol. 2013 Mar-Apr;12(2):248-55.